TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02245230
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
Study: NCT00902512
Drug: Blood samples for the analysis of sildenafil in plasma
Normalized name: blood plasma
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blood samples for the analysis of sildenafil in plasma
Study: NCT01326676
Drug: Polypill: Red Heart Pill
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
Study: NCT01326676
Drug: Usual medication
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
Study: NCT02392676
Drug: OLAPARIB
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study: NCT00946751
Drug: Levetiracetam Tablets, 750 mg (Sandoz Inc.)
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00902512
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg CT administered without water single dose
Study: NCT02440685
Drug: ASN002 Dose Escalation
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses of ASN002 assigned by cohort
Study: NCT02750319
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03802786
Drug: Imeglimin
Normalized name: imeglimin
DrugBank: Imeglimin (DB12509)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Single administration dose of imeglimin
Study: NCT01923948
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 150 mg oral dose of Pregabalin given before surgery
Study: NCT02971306
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
Study: NCT02750319
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02971306
Drug: n-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
Study: NCT03601507
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00073138
Drug: ABT-751
Normalized name: ABT-751
DrugBank: ABT-751 (DB12254)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004192
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004192
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004192
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004192
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00083304
Drug: Efaproxiral
Normalized name: EFAPROXIRAL
DrugBank: Efaproxiral (DB08486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days.
Study: NCT00323310
Drug: gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
Study: NCT00365924
Drug: Forteo
Normalized name: Forteo
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Open label single arm study with Forteo as an intervention
Study: NCT00994149
Drug: Diazoxide
Normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/kg/d divide every 8 hours
Study: NCT03061513
Drug: Ubiquinol
Normalized name: Ubiquinol
DrugBank: Ubiquinol (DB11340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol caplets 600mg/day
Study: NCT04227990
Drug: Plinabulin
Normalized name: Plinabulin
DrugBank: Plinabulin (DB05992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
Study: NCT01755325
Drug: Compound realgar natural indigo Tablet
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd
Study: NCT04227990
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
Study: NCT02939495
Drug: Dapoxetine/Sildenafil 30/50 mg film coated tablet
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet before sexual intercourse
Study: NCT00370799
Drug: Caudal epidural injection
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: group 1: Caudal epidural injection local anesthetics only
Study: NCT04366739
Drug: CHLORPROMAZINE (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum
Study: NCT00214981
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01738867
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
Study: NCT04245319
Drug: Acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive the drug and the effect on repigmentation on vitiligo lesions will be observed
Study: NCT01887184
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 1.5mcg/kg was given intranasally
Study: NCT00056004
Drug: zileuton
Normalized name: Zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01959412
Drug: Indacaterol 27.5 mcg
Normalized name: indacaterol 27.5 MCG / glycopyrrolate 15.6 MCG Inhalation Powder
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: indacaterol 27.5 mcg twice daily inhaled once via inhaler
Study: NCT01959412
Drug: Indacaterol 37.5
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 37.5 mcg once daily, inhaled once via inhaler
Study: NCT01959412
Drug: Indacaterol 55 mcg
Normalized name: indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 55 mcg once daily, inhaled once via inhaler
Study: NCT01959412
Drug: Indacaterol 75 mcg
Normalized name: indacaterol 75 MCG Inhalation Powder
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 75 mcg once daily, inhaled once via inhaler
Study: NCT01959412
Drug: Indacaterol 150 mcg
Normalized name: indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150 mcg once daily, inhaled once via inhaler
Study: NCT01013090
Drug: Six percent hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
Study: NCT02624453
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
Study: NCT00079482
Drug: CEP-701
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00079482
Drug: high-dose cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT04134728
Drug: Placebo to GSK3196165/ Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/PFS to be administered SC.
Study: NCT00040950
Drug: agatolimod sodium
Normalized name: AGATOLIMOD SODIUM
DrugBank: Agatolimod (DB15018)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736371
Drug: 1% Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
Study: NCT01736371
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group the maintenance of anesthesia is maintained by only propofol infusion.
Study: NCT01736371
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
Study: NCT02386449
Drug: mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02386449
Drug: Bisacodyl
Normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02209701
Drug: Porfiromycin
Normalized name: Porfiromycin
DrugBank: Porfiromycin (DB06478)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00398099
Drug: MK0826, ertapenem sodium / Duration of Treatment: 14 Days
DrugBank: Ertapenem (DB00303)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04104776
Drug: CPI-0209
Normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-0209 alone
Study: NCT00637416
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 30 mg taken by mouth daily for 3 months
Study: NCT02244229
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02244229
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04346329
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated group
Study: NCT02862873
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00604630
Drug: recombinant human erythropoietin alfa
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
Study: NCT01826448
Drug: vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04406649
Drug: Dihydroergotamine
Normalized name: Dihydroergotamine
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
Study: NCT03015324
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine
Study: NCT02612922
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 600 mg administered orally twice daily for five days
Study: NCT04263415
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: semaglutide inrun period of 4 weeks with 0.5mg/week s.c. followed by 1mg/week sc for 12 weeks
Study: NCT02818270
Drug: Salbutamol
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
Study: NCT02818270
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
Study: NCT00310596
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,1mmol/kg at 10 mL/15 sec
Study: NCT00310596
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: same dose as arm 1 at bolus rate (2mL/sec)
Study: NCT00310596
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,3mmol/kg at 10 mL/15 sec
Study: NCT00310596
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: same dose as arm 3 at bolus rate (2mL/sec)
Study: NCT00310596
Drug: Moxifloxacin (BAY12-8039)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg at 0,07 mL/sec over 60 min
Study: NCT04465071
Drug: AEONTM Repair and AEONTM Protect Plus lubricating eye drops
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEONTM Repair and AEONTM Protect Plus lubricating eye drops
Study: NCT03933397
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg for participants weighing \<50 kgs, 6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
Study: NCT03933397
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg for participants weighing \<60 kgs, 1.5 mg for participants weighing 60 - 89.9 kgs, and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
Study: NCT03367715
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: study treatment on Day 1 with one dose of nivolumab 3 mg/kg
Study: NCT03367715
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: study treatment on Day 1 with one dose of ipilimumab 1mg/kg
Study: NCT02671097
Drug: BAY1841788 (ODM-201)
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
Study: NCT01242605
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
Study: NCT01242605
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m\*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
Study: NCT01242605
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin: 25 mg/m\*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
Study: NCT01405612
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral administration on Day 1 or Day 5
Study: NCT01405612
Drug: Ulimorelin
Normalized name: Ulimorelin
DrugBank: Ulimorelin (DB12128)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 480 micrograms/kg on Days 1 to 5
Study: NCT03910088
Drug: Pregabalin 100Mg Oral Cap
Normalized name: PREGABALIN 100MG ORAL CAP
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: giving a drug to relieve post-dural puncture headache
Study: NCT01149915
Drug: TH-302
Normalized name: TH-9402 free base
DrugBank: TH-9402 free base (DB17148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
Study: NCT02820857
Drug: Folfiri-bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
Study: NCT00362843
Drug: [15-O]water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03370406
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intralesional injections of 50mg/ml over a 3 week period.
Study: NCT03370406
Drug: Imiquimod 5% cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical application of 5% cream over a 3 week period.
Study: NCT05217303
Drug: HL-085
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
Study: NCT01037907
Drug: Pleneva TM BGC20-0134
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo or 5 g dose
Study: NCT01348386
Drug: Hydroxide Potassium
Normalized name: Calcium Hydroxide
DrugBank: Hydroxide ion (DB14522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
Study: NCT03680183
Drug: Entecavir 1Mg Oral Tablet
Normalized name: Entecavir 1mg Oral tablet
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
Study: NCT02155920
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
Study: NCT01142622
Drug: Ropivacaine nebulization
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
Study: NCT01142622
Drug: Ropivacaine instillation
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
Study: NCT01568294
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
Study: NCT04289792
Drug: nab-Paclitaxel+Gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: nab-Paclitaxel 125 mg/m2 IV over approximately 30-45 min on Days 1 and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 min on Days 1 and 15 of each 28-day cycle for 6 cycles.